Form 8-K FluMist Approved by the FDA
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
------------------------------------------------------------------------------------------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report
June 18, 2003
MedImmune, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-19131 52-1555759
(State or other jurisdiction of (Commission File No.) (I. R. S. Employer
incorporation or organization) Identification No.)
35 West Watkins Mill Road, Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (301) 417-0770
ITEM 5. Other Events
On June 17, 2003, MedImmune, Inc. (the "Company") and Wyeth Vaccines, a business unit of Wyeth
Pharmaceuticals, a division of Wyeth, issued a press release announcing the approval of FluMist™,
the first influenza vaccine delivered as a nasal mist available in the United States for healthy
people, by the U.S. Food and Drug Administration. A copy of the Company's press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 7. Exhibits
c. Exhibits
Exhibit Description
------- -----------
Ex. 99.1 Press release, dated June 17, 2003, "FDA Approves FluMist™--First
Nasal Mist Influenza Vaccine Licensed in the U.S.--First Innovation
in Flu Vaccine Delivery in Over 50 Years"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDIMMUNE, INC.
Date: June 18, 2003 /s/: Lota S. Zoth
Lota S. Zoth
Vice President and Controller